Test environment running 7.6.6

Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Bone turnover 18 months after a single intravenous dose of zoledronic acid

Date

Authors

Borba, LuizAlencar

Da Paz Filho, Gilberto

kulak, carolina A

Seibel, Markus J.

Bilezikian, John P

Publisher

Blackwell Publishing Ltd

Abstract

Zoledronic acid inhibits bone resorption for up to 12 months. It is not known whether the duration of this antiresorptive effect extends beyond this period of time. The aim of this study was to evaluate the changes in bone turnover at 12 months (T12) and

Keywords

Keywords: alkaline phosphatase bone isoenzyme; calcium carbonate; carboxy terminal telopeptide; colecalciferol; zoledronic acid; adult; aged; article; bone density; bone turnover; clinical article; clinical trial; drug effect; drug efficacy; female; follow up; hip;

URI

http://hdl.handle.net/1885/30377

Collections

Open Access Research

Source

International Journal of Clinical Practice

Type

Journal article

DOI

10.1111/j.1742-1241.2007.01392.x

Restricted until

2037-12-31

Downloads

File

Description

01_Borba_Bone_turnover_18_months_after_2007.pdf (179.52 KB)